Who is sponsoring NCT02822404?

NCT02822404 is sponsored by University Hospital, Toulouse.

What drugs are being tested in NCT02822404?

Interventions in NCT02822404: Urinary and blood sample for Cystatine dosage.

What condition does NCT02822404 study?

NCT02822404 studies Kidney Diseases.

Is NCT02822404 still recruiting?

NCT02822404 is currently completed. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT02822404: CysPed

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Description of the Cystatin C as an Early Nephrotoxic Bio-marker in Pediatric Oncology

Completed NA Last updated 1 April 2026

What this trial tests

NA trial testing Urinary and blood sample for Cystatine dosage in Kidney Diseases in 42 participants. Completed in 4 May 2021.

Timeline

17 February 2012

Primary endpoint
4 May 2021

4 May 2021

Quick facts

Lead sponsor	University Hospital, Toulouse
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	42
Start date	17 February 2012
Primary completion	4 May 2021
Estimated completion	4 May 2021
Sites	1 location across France

Drugs / interventions tested

Urinary and blood sample for Cystatine dosage

Conditions studied

Kidney Diseases — all drugs for Kidney Diseases →

Sponsor

University Hospital, Toulouse

Who can join

Under 18, any sex, with Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cisplatin and ifosfamide are commonly used drugs in chemotherapy. They are known to involve renal toxic threats in children given their immature kidney. This toxicity is increased especially after nephrectomy and/or concomitant radiotherapy. In pediatric oncology, the available evaluation methods of the renal function could be very restrictive to perform on children. In this study, the investigators intend to test the use of the cystatin C as an effective and reliable biological marker of renal toxicity in children treated with cisplatin and / or ifosfamide.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Nephrotoxicity in cancer treatment: An update.
Chen C, Xie D, Gewirtz DA, Li N. · · 2022 · cited 18× · PMID 35779877 · DOI 10.1016/bs.acr.2022.03.005
Plasma cystatin C is a marker of renal glomerular injury in children treated with cisplatin or ifosfamide.
Lambert M, White-Koning M, Alonso M, Garnier A, et al · · 2021 · cited 6× · PMID 33058496 · DOI 10.1002/pbc.28747
A population pharmacokinetic approach to compare <sup>51</sup>Cr-EDTA and <sup>99 m</sup>Tc-DTPA clearances in measuring renal glomerular filtration rate in oncopediatrics.
Gracia M, Ankaoua V, Alonso M, Pasquet M, et al · · 2025 · cited 1× · PMID 40439777 · DOI 10.1007/s00467-025-06828-9

Verify or expand the search:

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting

Other University Hospital, Toulouse trials

Trials by the same sponsor.

NCT07497750 — Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver D · NA · not yet recruiting
NCT07507240 — The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Tre · NA · not yet recruiting
NCT07524088 — Contamination of Young Children Hair During Acute Cannabis Intoxication · NA · not yet recruiting
NCT07470580 — Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension · NA · not yet recruiting
NCT07423988 — Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the W · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02822404 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Toulouse
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02822404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing